CZ122697A3 - Preparations and methods of treating disseminated sclerosis - Google Patents

Preparations and methods of treating disseminated sclerosis Download PDF

Info

Publication number
CZ122697A3
CZ122697A3 CZ971226A CZ122697A CZ122697A3 CZ 122697 A3 CZ122697 A3 CZ 122697A3 CZ 971226 A CZ971226 A CZ 971226A CZ 122697 A CZ122697 A CZ 122697A CZ 122697 A3 CZ122697 A3 CZ 122697A3
Authority
CZ
Czechia
Prior art keywords
mbp
peptide
group
peptides
multiple sclerosis
Prior art date
Application number
CZ971226A
Other languages
Czech (cs)
English (en)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of CZ122697A3 publication Critical patent/CZ122697A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ971226A 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis CZ122697A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
CZ122697A3 true CZ122697A3 (en) 1997-09-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ971226A CZ122697A3 (en) 1994-10-25 1995-10-25 Preparations and methods of treating disseminated sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (sv)
JP (1) JPH10504039A (sv)
AU (1) AU4278296A (sv)
BR (1) BR9509438A (sv)
CA (1) CA2203629A1 (sv)
CZ (1) CZ122697A3 (sv)
FI (1) FI971750A (sv)
HU (1) HUT77047A (sv)
IL (1) IL115766A0 (sv)
IS (1) IS4466A (sv)
NO (1) NO971900L (sv)
PL (1) PL324091A1 (sv)
SI (1) SI9520118A (sv)
SK (1) SK51297A3 (sv)
WO (1) WO1996012737A2 (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
ES2314515T3 (es) 1996-03-21 2009-03-16 Circassia Limited Peptidos cripticos y metodo para su identificacion.
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
JP2002513558A (ja) * 1998-05-05 2002-05-14 コリクサ コーポレイション ミエリン塩基性タンパク質ペプチドおよびその使用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CN1656222B (zh) 2002-03-27 2011-11-30 艾格拉治疗公司 反义iap核碱基寡聚物及其应用
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF
CA2757287C (en) * 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
AU2009354040A1 (en) 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
EP2688904B1 (en) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
US10188707B2 (en) 2014-01-13 2019-01-29 Berg, LLC Enolase 1 (Eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856566T2 (de) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
KR0185747B1 (ko) * 1989-12-20 1999-05-01 마리아 아이. 마마리노스 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
AU651097B2 (en) * 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
DE69332518T2 (de) * 1992-02-28 2003-09-04 Autoimmune Inc Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
ATE212358T1 (de) * 1992-04-09 2002-02-15 Autoimmune Inc Unterdrückung der proliferation von t-zellen mittels peptidfragmenten des basischen proteins aus myelin
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
AU7725894A (en) * 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
CA2187345A1 (en) * 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
BR9507451A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
FI971750A (sv) 1997-06-24
NO971900D0 (no) 1997-04-24
SK51297A3 (en) 1998-03-04
NO971900L (no) 1997-06-25
AU4278296A (en) 1996-05-15
WO1996012737A2 (en) 1996-05-02
CA2203629A1 (en) 1996-05-02
EP0787147A1 (en) 1997-08-06
IL115766A0 (en) 1996-01-19
WO1996012737A3 (en) 1996-10-10
HUT77047A (hu) 1998-03-02
FI971750A0 (sv) 1997-04-24
SI9520118A (sl) 1998-08-31
IS4466A (is) 1997-04-17
BR9509438A (pt) 1997-12-23
PL324091A1 (en) 1998-05-11
JPH10504039A (ja) 1998-04-14

Similar Documents

Publication Publication Date Title
CZ122697A3 (en) Preparations and methods of treating disseminated sclerosis
EP1311542B1 (en) Tolerogenic peptides
US5858980A (en) Peptide fragments of myelin basic protein
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
WO1996012737A9 (en) Compositions and treatment for multiple sclerosis
WO2005087261A2 (en) Identification of self and non-self antigens implicated in autoimmune diseases
Samson et al. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes.
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
TW496872B (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
JP2000512277A (ja) ペプチド誘導体
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
MXPA04007510A (es) Peptidos tolerogenicos de la proteina basica de mielina.
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
EP0922057A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
JP2006525813A (ja) １型糖尿病において罹患性病原性ｔ細胞により標的とされる抗原ならびにこれの使用
EP2945966B1 (en) Peptide
KR100540417B1 (ko) 펩티드 면역 요법 치료제
CA3182369A1 (en) Combination treatment for fumarate-related diseases
Shen et al. Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse
US20230414732A1 (en) Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
EP2227486B1 (en) Peptide analogues and conjugates thereof
US6207389B1 (en) Methods of controlling T lymphocyte mediated immune responses
WO2020072992A1 (en) Recombinant polypeptides comprising modified mhc class ii drα1 domains and methods of use

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic